Collplant Biotechnologies Ltd. · NASDAQ:CLGN
Collplant Biotechnologies — Investor Presentation (April 2023)
37 slides from Collplant Biotechnologies's investor presentation, Apr 11, 2023
Slide 1: Company Overview
1 APRIL 202 3 NASDAQ: CLGN Company Overview Our Mission Developing and delivering collagen technology and regenerative medicine products to improve and prolong lives
Slide 2: Certain statements in this presentation constitute "forward - looking statements" within the meaning of
2 Certain statements in this presentation constitute "forward - looking statements" within the meaning of Section 27 A of the Securities Act and Section 21 E of the Securities Exchange Act and are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "inte
Slide 3: Our Company Vision
3 Imagine a future where… There will be an unlimited supply of spare parts for the human body , including life - saving organs Medical treatment will be tailored for the individual characteristics of each patient Drugs will be developed without the need for animal testing We aspire to become the lea
Slide 4: Investment Thesis
4 I nvestment T hesis Pioneering Proprietary, Plant - Based Technology Platform Addressing Multi - billion - dollar markets Broadly applicable, clinically validated technology Strategic agreement with global top - tier pharmaceutical company AbbVie Highly seasoned management team Strong cash positio
Slide 5: At a Glance
5 At - a Glance • * Figures as of April 4 , 2023 NASDAQ (CLGN) (listed since 2018) cGMP production facility that utilizes proprietary production processes Shares outstanding: ~ 11 M Well - capitalized Market cap*: ~$ 80 M* Avg trading vol ( 3 m)*: 15 M shares/day Clinically validated in Europe Re -
Slide 6: Collagen is an Essential Component of the Human Body
6 Collagen is an Essential Component of the Human Body (e.g. cartilage, bones, tendons, ligaments, skin and vasculature) 25 % to 35 % of the whole - body protein content Ideal scaffolding molecule for regenerative medicine The main structural protein in the extracellular matrix found in the body ’ s
Slide 7: Our Technology Platform Produces Human Collagen in Plants at Mass Scale
7 4 Five human genes essential to the synthesis of Type 1 collagen are introduced into tobacco plants to produce rhCollagen identical to human collagen but without an adverse immune response Our Technology Platform Produces Human Collagen in Plants at Mass - Scale N - propeptide C - propeptide COL1
Slide 8: rhCollagen: The Ideal Building Block for Regenerative Medicine
8 5 Animal Extracted Plant - derived = Cell binding domains rhCollagen: The I deal B uilding B lock for Regenerative Medicine Clear advantages over tissue - extracted (animal - derived) collagen Superior homogeneity allows for creating implants and biological inks with distinct physical properties I
Slide 9: How We are Applying our rhCollagen: Areas of Focus
9 Product Use Preclinical Clinical Commercial Status/Partner Aesthetic medicine Injectable tissue fillers Dermal/soft tissue fillers Injectable tissue fillers Photocurable dermal filler Regenerative medicine Breast implant Breast reconstruction & augmentation BioInks Tissues, organs, drug discovery
Slide 10: Diverse Product Pipeline, Associated with Significant IP
10 Diverse Product Pipeline, Associated with Significant IP Photocurable fillers designed to provide soft tissue regeneration and contouring Dermal/Soft Tissue Fillers Key Attributes: Enhanced and prolonged lifting capacity Tissue regeneration Contouring ability for improved aesthetic outcome Techno
Slide 11: Dermal/Soft Tissue Fillers
11 Dermal/Soft Tissue Fillers In collaboration with
Slide 12: Dermal Fillers: Market Overview
12 12 1. www.plasticsurgery.org/documents/News/Statistics/a2020/plastic - surgery - statistics - full - report - 2020.pdf 2. www.gminsights.com/industry - analysis/dermal - filler - market 3. www.medicalsparx.com/juvederm - hydrate 4. www.medicalsparx.com/buy - juvederm - ultra - plus - xc Dermal Fi
Slide 13: Collaboration Agreement with AbbVie
13 Collaboration Agreement with AbbVie Agreement Highlights Financial Highlights A worldwide exclusive development and commercialization agreement for dermal and soft tissue fillers for the medical aesthetics market Combines CollPlant ’ s proprietary rhCollagen technology and AbbVie's technology Rig
Slide 14: Unmet Need: Dermal Fillers To-Date Have Numerous Drawbacks
14 14 Unmet Need: Dermal Fillers To - Date Have Numerous Drawbacks Safety issues • Various adverse events, including inflammatory response • Potential for nodule formation Undesired physical outcome (unnatural look due to lack of pliability under skin) Short - lasting and require repeat injections
Slide 15: The New Shape of Beauty
15 The New Shape of Beauty Photocurable Dermal & Soft Tissue Filler
Slide 16: Photocurable Regenerative Soft Tissue Filler
16 Injection Sculpting Photocuring in - situ Filler Features: Contouring and regeneration may apply to other body areas Allows for regeneration and rejuvenation, extending effects and satisfaction with each injection Enhanced lifting capacity Adhesion and retention to the host tissue Allows for cont
Slide 17: Key Attributes
17 Key Attributes Injection Sculpting Allows for molding of material for a natural look; prevents encapsulation nodules Photocuring in - situ Strong scaffolding allows for skin lifting and rejuvenation Tissue regeneration Reduces repeat injections Easy injection (30G needle) Sculpting before curing
Slide 18: Evolution of Hyaluronic Acid (HA) Dermal Filler
18 Currently HA marketed products CONTOURA ® Lifting Rejuvenation Contouring Evolution of Hyaluronic Acid (HA) Dermal Filler
Slide 19: Breast Reconstruction / Augmentation
19 Breast Reconstruction / Augmentation CollPlant’s first - ever regenerating breast implant
Slide 20: Breast Implants Market Overview
20 Breast Implants Market Overview 60 % Breast augmentation 21 % Breast Lift reconstruction Procedure (US segmentation) Current breast reconstruction is based on synthetic breast implantation, free flap surgery/autologous fat tissue transfer - all of which replace tissue rather than regenerate it. ~
Slide 21: Unmet Need: The Ability to Regenerate Breast Tissue
21 Unmet Need: The Ability to Regenerate Breast Tissue No regenerative breast implant exists FDA alert: Patients with breast implants have an increased risk of developing breast implant Associated - Anaplastic Large Cell Lymphoma (Feb 2019) * * https://www.fda.gov/medical - devices/breast - implants
Slide 22: CollPlant's 3D Bioprinted Regenerative Breast Implants
22 Breast scaffold bioprinting rhCollagen + ECM components Implantation and vascularization Implant degrades over time and replaced by newly formed tissue CollPlant ’ s 3 D Bioprinted Regenerative Breast Implants for Aesthetic and Reconstructive Procedures A preclinical study demonstrated progressiv
Slide 23: Joint Development and Commercialization Agreement with Stratasys
23 Joint Development and Commercialization Agreement with Stratasys: Announced 4/4/2023 Co - development agreement with a leader in additive manufacturing with decades of 3 D printing experience Under the agreement, both companies have agreed to cross - promote each other’s bioprinting products Comb
Slide 24: Gut-on-a-Chip
24 Gut - on - a - C hip
Slide 25: rhCollagen-Based 3D Bioprinted Gut-on-a-Chip
25 Our rhCollagen - B ased 3 - D B ioprinted G ut - on - a - C hip Has the Potential to Shift D rug D iscovery and P ersonalized M edicine https://www.congress.gov/bill/ 117 th - congress/house - bill/ 2565 /text?r= 76 &s= 1 https://www.science.org/content/article/fda - no - longer - needs - require
Slide 26: Inflammatory Bowel Diseases: An Unmet Need
26 Inflammatory Bowl Diseases: An Example of an Unmet Need that Exists for IBD Patients Inflammatory bowel diseases, which include ulcerative colitis and Crohn’s disease, are characterized by chronic inflammation, a relapsing and remitting clinical course and life - long treatment. > 6 M ulcerative
Slide 27: Our Collaborators: Gut-on-a-Chip Technology
27 Our Collaborators: Gut - on - a - Chip Technology From Tel - Aviv University and Sheba Medical Center Co - development agreement with Tel - Aviv University and Sheba Medical Center Model designed to accurately mimic the human intestine tissue structure and function Patient - specific cells enable
Slide 28: 3D Bioprinted Tissues and Organs
28 3 - D Bioprinted Tissues and Organs
Slide 29: 3D bioprinting represents a wide range of development opportunities
29 3 D bioprinting represents a wide range of development opportunities Develop in - house or with collaborators Develop in c ollaboration with leading life sciences companies Development cost Time to market Tissues • Breast • Heart valve • Cornea • Skin • Cartilage Endocrine glands • Ovary • Pancre
Slide 30: rhCollagen-based BioInks enable high resolution printing of elastic scaffolds
30 rhCollagen - based BioInks enable high resolution printing of elastic scaffolds
Slide 31: Bioinks Competitive Landscape
31 Bioinks Competitive Landscape Collagen - based: • Tissue - extracted collagen (e.g. rat, bovine) • Synthetic peptides Drawbacks of most commonly used bioinks: • Unsuitable for clinical use • May elicit immune response • High batch - to - batch variability • Small scale production Non - collagen -
Slide 32: Collink.3D: rhCollagen-bioink platform for biofabrication
32 Collink. 3 D : rhCollagen - bioink platform for biofabrication CollPlant Collink. 3 D TM : A xeno - free human - collagen based BioInk, perfectly mimicking properties of the native tissue or organ Cytocompatible , Biofunctional Animal - free : excellent safety profile non immunogenic Optimal rheo
Slide 33: rhCollagen BioInk components
33 rhCollagen BioInk components Direct Ink Writing (DIW) Inkjet Projection Stereolithography Laser Induced Forward Transfer (LIFT) Polymers (physical properties) Ceramics (hard tissue) Nanoparticles (sustained release/physical properties ECM components (biological/ physical properties) CollInk - 3D
Slide 34: Seasoned Management Team
34 Seasoned Management Team with Engineering, Pharmaceutical, Device and Life Sciences Experience Yehiel Tal CEO Regentis Biomaterials ProChon Biotech Kulicke & Soffa Industries Eran Rotem Deputy CEO & CFO Tefron , CFO (NYSE,TASE) Healthcare Tech., CFO (NASDAQ) & Gamida E&Y Elana Gazal , PhD VP R&D
Slide 35: Our Partners
35 Our Partners Developme nt and commercialization agreement Joint development agreement Universal BioInk Industry committee Scalable manufacturing of tissue engineered products 23 Supply agreement Developme nt and commercialization agreement
Slide 36: Investment Summary
36 I nvestment Summary Pioneering proprietary, plant - based technology platform The only commercially viable technology that can produce truly human collagen at mass scale and without reliance on animal tissue Addressing Multi - billion - dollar markets Innovative rhCollagen technology initially fo
Slide 37: Thank you
Thank you CollPlant fa eae i
CollPlant Biotechnologies — Investor Presentation (April 2023) on 6ix